サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1373202

LBP (生きた生物学的製剤)・微生物CDMO市場- 世界の産業規模、動向、競合、機会、予測、2018年-2028年

Live Biotherapeutics Products & Microbe CDMO Market - Global Industry Size, Share, Trends, Competition, Opportunity, & Forecast, 2018-2028 Segmented By Application, By Product, By Type of Formulation, By Scale of Operation, By Region & Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 177 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

LBP (生きた生物学的製剤)・微生物CDMO市場- 世界の産業規模、動向、競合、機会、予測、2018年-2028年
出版日: 2023年10月03日
発行: TechSci Research
ページ情報: 英文 177 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のLBP (生きた生物学的製剤)市場は、2024～2028年の予測期間中に高いCAGRで上昇すると予測されています。

心血管疾患、糖尿病、慢性呼吸器疾患、がん、慢性腎臓病など、特定の慢性疾患の有病率が様々な国で増加していることから、予測期間において、世界のLBP (生きた生物学的製剤)および微生物CDMO市場は有利な成長を記録すると予想されます。さらに、身体的および精神的健康のための個別化された医薬品に対する世界中の人々の嗜好の高まりは、今後数年間、LBP (生きた生物学的製剤)および微生物CDMO市場の成長を促進すると予想されます。

調査範囲

本レポートでは、世界のLBP (生きた生物学的製剤)および微生物CDMO市場を、以下に詳述する業界動向に加えて、以下のカテゴリーに分類しています。

LBP (生きた生物学的製剤)および微生物CDMO市場、用途別

  • C.ディフィシル
  • クローン病
  • IBS
  • 糖尿病
  • その他

LBP (生きた生物学的製剤)と微生物CDMO市場、製品別

  • 原薬
  • FDF類

LBP (生きた生物学的製剤)および微生物CDMO市場：製品タイプ別

  • 固形製剤
  • 経口液剤
  • 注射剤
  • その他

LBP (生きた生物学的製剤)および微生物CDMO市場：事業規模別

  • 前臨床規模
  • 臨床スケール事業
  • 商業スケール事業

LBP (生きた生物学的製剤)および微生物CDMO市場：地域別

  • 北米
  • 米国
  • カナダ
  • メキシコ
  • アジア太平洋
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • 日本
  • 欧州
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア
  • 南米
  • ブラジル
  • アルゼンチン
  • コロンビア
  • 中東＆アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

競合情勢

  • 企業プロファイル：世界のLBP (生きた生物学的製剤)および微生物CDMO市場における主要企業の詳細分析

利用可能なカスタマイズ：

  • TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のLBP (生きた生物学的製剤)と微生物CDMO市場の展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • 用途別（C.difficle、クローンズ病、IBS、糖尿病、その他）
    • 製品別（API、FDF）
    • 製剤タイプ別（固形製剤、経口液剤、注射剤、その他）
    • 事業規模別（前臨床規模事業、臨床規模事業、商業規模事業）
    • 地域別
    • 企業別（2022年）
  • 製品市場マップ

第6章 北米のLBP (生きた生物学的製剤)と微生物CDMO市場の展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェア・予測
    • 用途別
    • 製品別
    • 製剤タイプ別
    • 事業規模別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州のLBP (生きた生物学的製剤)と微生物CDMO市場の展望

  • 市場規模と予測
    • 金額・数量別
  • 市場シェアと予測
    • 用途別
    • 製品別
    • 製剤タイプ別
    • 事業規模別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域のLBP (生きた生物学的製剤)と微生物CDMO市場の展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • 用途別
    • 製品別
    • 製剤タイプ別
    • 事業規模別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米LBP (生きた生物学的製剤)と微生物CDMO市場の展望

  • 市場規模と予測
    • 金額・数量別
  • 市場シェアと予測
    • 用途別
    • 製品別
    • 製剤タイプ別
    • 事業規模別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのLBP (生きた生物学的製剤)と微生物CDMO市場の展望

  • 市場規模・予測
    • 金額・数量別
  • 市場シェアと予測
    • 用途別
    • 製品別
    • 製剤タイプ別
    • 事業規模別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

第13章 PESTLE分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Arranta Bio Holdings LLC.
  • 4D Pharma plc.
  • Cerbios-Pharma S.A.
  • Biose Industrie
  • Assembly Biosciences, Inc.
  • Wacker Chemie AG
  • Quay Pharmaceuticals Ltd.
  • Bacthera AG
  • LONZA
  • Inpac Probiotics

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 15742

Global Live Biotherapeutics Products (LBPs) Market is anticipated to rise at a high CAGR during the forecast period, 2024-2028. Growing prevalence of certain chronic diseases such as cardiovascular diseases, diabetes, chronic respiratory diseases, cancer, and chronic kidney disease across various countries are expected to register a lucrative growth to global live biotherapeutics products and microbe CDMO market in the forecast period. Moreover, growing preference of people around the world towards personalized medicines for physical and mental health are expected to propel the growth of live biotherapeutics products and microbe CDMO market in upcoming years.

Live Biotherapeutics Products (LBPs) are a type of therapeutic product that utilize living microbes to treat various medical conditions. Some of the commonly available live biotherapeutics products available in the market includes Lactobacillus acidophilus, Bifidobacterium lactis, Streptococcus thermophilus, Saccharomyces boulardii, and Escherichia coli Nissle. These microbes, such as bacteria or yeast, are typically found in the gut microbiome and play a critical role in maintaining human health. LBPs work by introducing these microbes into the body in a controlled manner to restore or enhance their function.

A Microbial Contract Development and Manufacturing Organization (CDMO) is a company that specializes in the development and manufacturing of microbial-based products, including live biotherapeutics product. Microbe CDMOs can provide a range of services, including strain development, fermentation optimization, downstream processing, and quality control. CDMO activities can be broadly categorized into three categories such as product development, manufacture of active pharmaceutical ingredients (API), and manufacture of finished dosage forms (FDF). There are around 500 Contract Development and Manufacturing Organization established in the world. Among them, Switzerland-based Lonza is the leading CDMO industry functioning across the world.

Increasing Prevalence of Chronic Diseases

Chronic diseases are defined broadly as conditions that progress slowly and persist over an extended period. Some of the major risk factors which lead to the development of chronic illness inside human body include intake of unbalanced diet, consumption of alcohol, smoking cigarettes, physical inactivity, and others. Cardiovascular diseases, Cancer, and diabetes are three most prevailing chronic diseases in the world which are thereby increasing the mortality of every country in the forecast period. According to the report published by Pan American Health Organization (PAHO) in 2019, Ischemic heart disease accounted for 73.6 deaths per 100,000 population in the world, followed by stroke with 32.3 deaths, other circulatory diseases with 14.8 deaths, hypersensitive heart disease with 10.6 deaths, cardiomyopathy, myocarditis, and endocarditis with 5.1 deaths and rheumatic heart disease with 0.7 deaths of total population across the world. After cardiovascular diseases, cancer has been reported as second major reason behind the growing mortality rate of various developing countries across the world. As per the report published by World Health Organization (WHO) in 2022, it has been observed that lung cancer has been the most prominent type of cancer prevailing across the world accounting for 1.80 million deaths, followed by 9,16,000 deaths caused by colon and rectum cancer, 8,30,000 deaths due to liver cancer, 7,69,000 deaths by stomach cancer and 6,85,000 deaths caused by breast cancer. Live biotherapeutic products are designed to modulate the gut microbiome which plays a major role in maintaining a healthy immune system and preventing chronic diseases. Moreover, microbe CDMOs provide customized solutions for the development, manufacturing, and scale-up of microbial products for clinical trials and commercial use. Other health problems which can affect the human body along with prevalence of chronic diseases are expected to propel the growth of global biotherapeutics products and microbe CDMO market in the forecast period.

Rise in Demand for Personalized Medicines

The growing demand for personalized medicines is indeed a significant driver of the global biotherapeutics products and microbe CDMO (Contract Development and Manufacturing Organization) market. Biotherapeutics products, including personalized medicines, are a major growth area of pharmaceutical industry. These products are derived from biological sources, such as living cells, and can be used to treat a wide range of diseases, including cancer, autoimmune disorders, and genetic diseases. Moreover, microbe CDMOs are specialized in the development and manufacturing of biotherapeutics products, including personalized medicines, using microbial systems such as bacteria, yeast, and fungi. These CDMOs offer a range of services, including cell line development, process development, analytical development, and manufacturing. The growing demand for personalized medicines has led to an increase in the demand for these services which are further projected to register an impressive growth to Global Biotherapeutics Products and Microbe CDMO market in upcoming years.

Market Segmentation

Global live biotherapeutics products and microbe CDMO market is segmented based on application, product, type of formulation, scale of operation, company, and region. In terms of application, the live biotherapeutics products and microbe CDMO market is categorized into C.difficle, Crohns disease, IBS, diabetes, and others. Based on product, the global live biotherapeutics products and microbe CDMO market is fragmented into APIs and FDFs. Based on type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on scale of operation, the global live biotherapeutics products and microbe CDMO market is fragmented into preclinical scale operations, clinical scale operations, and commercial scale operations.

Market Players

Arranta Bio Holdings LLC., 4D Pharma plc., Cerbios-Pharma S.A., Biose Industrie, Assembly Biosciences, Inc., Wacker Chemie AG, Quay Pharmaceuticals Ltd., Bacthera AG, LONZA, and Inpac Probiotics are the major players of global live biotherapeutics products and microbe CDMO market.

Report Scope:

In this report, Global Live Biotherapeutics Products and Microbe CDMO Market has been segmented into following categories, in addition to the industry trends which have also been detailed below.

Live Biotherapeutics Products and Microbe CDMO Market, By Application:

  • C.difficle
  • Crohns disease
  • IBS
  • Diabetes
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Product:

  • APIs
  • FDFs

Live Biotherapeutics Products and Microbe CDMO Market, By Type of Formulation:

  • Solid Formulations
  • Oral Liquids
  • Injectables
  • Others

Live Biotherapeutics Products and Microbe CDMO Market, By Scale of Operation:

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Live Biotherapeutics Products and Microbe CDMO Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Global Live Biotherapeutics Products and Microbe CDMO Market

Available Customizations:

  • With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
    • 5.2.2. By Product (APIs, FDFs)
    • 5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
    • 5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Product Market Map

6. North America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Product
    • 6.2.3. By Type of Formulation
    • 6.2.4. By Scale of Operation
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value & Volume
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Type of Formulation
        • 6.3.1.2.4. By Scale of operation
    • 6.3.2. Mexico Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value & Volume
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Type of Formulation
        • 6.3.2.2.4. By Scale of Operation
    • 6.3.3. Canada Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value & Volume
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Type of Formulation
        • 6.3.3.2.4. By Scale of Operation

7. Europe Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Product
    • 7.2.3. By Type of Formulation
    • 7.2.4. By Scale of Operation
  • 7.3 Europe: Country Analysis
    • 7.3.1. France Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value & Volume
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Type of Formulation
        • 7.3.1.2.4. By Scale of Operation
    • 7.3.2. Germany Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value & Volume
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Type of Formulation
        • 7.3.2.2.4. By Scale of Operation
    • 7.3.3. United Kingdom Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value & Volume
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Type of Formulation
        • 7.3.3.2.4. By Scale of Operation
    • 7.3.4. Italy Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value & Volume
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Type of Formulation
        • 7.3.4.2.4. By Scale of Operation
    • 7.3.5. Spain Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value & Volume
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Type of Formulation
        • 7.3.5.2.4. By Scale of Operation

8. Asia-Pacific Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Product
    • 8.2.3. By Type of Formulation
    • 8.2.4. By Scale of Operation
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value & Volume
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Type of Formulation
        • 8.3.1.2.4. By Scale of Operation
    • 8.3.2. India Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value & Volume
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Type of Formulation
        • 8.3.2.2.4. By Scale of Operation
    • 8.3.3. South Korea Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value & Volume
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Type of Formulation
        • 8.3.3.2.4. By Scale of Operation
    • 8.3.4. Japan Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value & Volume
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Type of Formulation
        • 8.3.4.2.4. By Scale of Operation
    • 8.3.5. Australia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value & Volume
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Type of Formulation
        • 8.3.5.2.4. By Scale of Operation

9. South America Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Product
    • 9.2.3. By Type of Formulation
    • 9.2.4. By Scale of Operation
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value & Volume
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Type of Formulation
        • 9.3.1.2.4. BY Scale of Operation
    • 9.3.2. Argentina Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value & Volume
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Type of Formulation
        • 9.3.2.2.4. By Scale of Operation
    • 9.3.3. Colombia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value & Volume
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Type of Formulation
        • 9.3.3.2.4. By Scale of Operation

10. Middle East and Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Product
    • 10.2.3. By Type of Formulation
    • 10.2.4. By Scale of Operation
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value & Volume
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Type of Formulation
        • 10.3.1.2.4. By Scale of Operation
    • 10.3.2. Saudi Arabia Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value & Volume
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Type of Formulation
        • 10.3.2.2.4. By Scale of Operation
    • 10.3.3. UAE Live Biotherapeutics Products and Microbe CDMO Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value & Volume
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Type of Formulation
        • 10.3.3.2.4. By Scale of Operation

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Arranta Bio Holdings LLC.
    • 15.6.2. 4D Pharma plc.
    • 15.6.3. Cerbios-Pharma S.A.
    • 15.6.4. Biose Industrie
    • 15.6.5. Assembly Biosciences, Inc.
    • 15.6.6. Wacker Chemie AG
    • 15.6.7. Quay Pharmaceuticals Ltd.
    • 15.6.8. Bacthera AG
    • 15.6.9. LONZA
    • 15.6.10. Inpac Probiotics

16. Strategic Recommendations

17. About Us & Disclaimer